Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
The purpose of this randomized, double-masked, placebo-controlled study was to determine the efficacy and safety of risedronate in the prevention of vertebral fractures in postmenopausal women with established osteoporosis. The study was conducted at 80 study centers in Europe and Australia. Postmenopausal women (n = 1226) with two or more prevalent vertebral fractures received risedronate 2.5 or 5 mg/day or placebo; all subjects also received elemental calcium 1000 mg/day, and up to 500 IU/day vitamin D if baseline levels were low. The study duration was 3 years; however, the 2.5 mg group was discontinued by protocol amendment after 2 years. Lateral spinal radiographs were taken annually for assessment of vertebral fractures, and bone mineral density was measured by dual-energy X-ray absorptiometry at 6-month intervals. Risedronate 5 mg reduced the risk of new vertebral fractures by 49% over 3 years compared with control (p<0.001). A significant reduction of 61% was seen within the first year (p = 0.001). The fracture reduction with risedronate 2.5 mg was similar to that in the 5 mg group over 2 years. The risk of nonvertebral fractures was reduced by 33% compared with control over 3 years (p = 0.06). Risedronate significantly increased bone mineral density at the spine and hip within 6 months. The adverse-event profile of risedronate, including gastrointestinal adverse events, was similar to that of control. Risedronate 5 mg provides effective and well-tolerated therapy for…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is true for fracture patients with BMD in both the low bone mass and osteoporosis range [49–58].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“There is abundant evidence that the elevated risk of fracture in patients with osteoporosis by BMD is reduced with pharmacotherapy [52, 57, 59–70].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“There are abundant data that patients with spine and hip fractures will have reduced fracture risk if treated with pharmacologic therapy.”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“Risedronate reduces the incidence of vertebral fractures by 41 to 49 % and nonvertebral fractures by 36 % over 3 years, with significant risk reduction occurring within 1 year of treatment in patients with a prior vertebral fracture [51, 52].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“Risedronate reduces the incidence of vertebral fractures by 41 to 49 % and nonvertebral fractures by 36 % over 3 years, with significant risk reduction occurring within 1 year of treatment in patients with a prior vertebral fracture [51, 52].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Vertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Treatment of Postmenopausal Osteoporosis with Transdermal Estrogen
Lufkin, E. G., Wahner, H. W., O'Fallon, W. M., Hodgson, S. F., Kotowicz, M. A., Lane, A. W., Judd, H. L., Caplan, R. H., & Riggs, B. L. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-1-1 · Cited by 810
Estrogen Replacement Therapy and Fractures in Older Women
Cauley, J. A., Seeley, D. G., Ensrud, K., Ettinger, B., Black, D., Cummings, S. R., & and For The Study of Osteoporotic Fractures Research Group* (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-1-199501010-00002 · Cited by 809
Serum vitamin D concentrations among elderly people in Europe
van der Wielen, R. P. J., de Groot, L. C. P. G. M., van Staveren, W. A., Löwik, M. R. H., van den Berg, H., Haller, J., & Moreiras, O. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91266-5 · Cited by 772
Esophagitis Associated with the Use of Alendronate
de Groen, P. C., Lubbe, D. F., Hirsch, L. J., Daifotis, A., Stephenson, W., Freedholm, D., Pryor-Tillotson, S., Seleznick, M. J., Pinkas, H., & Wang, K. K. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351403 · Cited by 764
Treatment of Postmenopausal Osteoporosis
Eastell, R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803123381107 · Cited by 615
Self-citationGenant, H. K., Grampp, S., Glüer, C. C., Faulkner, K. G., Jergas, M., Engelke, K., Hagiwara, S., & van Kuijk, C. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650091002 · Cited by 610
Cited by
Items 501–600 of 1,002
2011 Up-Date of the Consensus Statement of the Spanish Society of Rheumatology on Osteoporosis
Pérez-Edo, L., Ruiz, A. A., Vilaseca, D. R., García-Vadillo, A., Gay, N. G., Peris, P., Eslava, A. T., Audera, C. B., Aresté, J. F., Rodríguez, L. M. A., et al. (2011) · Reumatología Clínica (English Edition) · doi:10.1016/j.reumae.2011.05.007 · Cited by 45
How long should patients take medications for postmenopausal osteoporosis?
Briot, K., Trémollières, F., Thomas, T., & Roux, C. (2006) · Joint Bone Spine · doi:10.1016/j.jbspin.2006.05.011 · Cited by 45
Self-citationSunyecz, J. A., Mucha, L., Başer, O., Barr, C. E., & Amonkar, M. M. (2008) · Osteoporosis International · doi:10.1007/s00198-008-0586-2 · Cited by 45
Hd, N., Em, H., Chou, R., Dana, T., Fu, R., & Bougatsos, C. (2010) · Europe PMC (PubMed Central) · Cited by 45
Migliore, A., Broccoli, S., Massafra, U., Cassol, M., & Frediani, B. (2013) · PubMed · Cited by 45
Intermittent Cyclic Tiludronate in the Treatment of Osteoporosis
Reginster, J., Christiansen, C., Roux, C., Fechtenbaum, J., Rouillon, A., & Tou, K. (2001) · Osteoporosis International · doi:10.1007/s001980170126 · Cited by 45
Self-citationDiagnosis and Management of Osteoporosis: A Comprehensive Review of Guidelines
Rentzeperi, E., Pegiou, S., Tsakiridis, I. G., Kalogiannidis, I. A., Kourtis, A., Mamopoulos, A. M., Athanasiadis, A. P., & Dagklis, T. (2023) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000001181 · Cited by 44
Cheng, Z., Yao, W., Zimmermann, E. A., Busse, C., Ritchie, R. O., & Lane, N. E. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.81005 · Cited by 44
Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis
Rhee, C. W., Lee, J.-S., Oh, S., Choi, N., & Park, B. J. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1608-z · Cited by 44
Mortality After Osteoporotic Fractures: What Proportion Is Caused by Fracture and Is Preventable?
Schousboe, J. T. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3216 · Cited by 44
Actualisation 2018 des recommandations françaises du traitement de l’ostéoporose post-ménopausique
Briot, K., Roux, C., Thomas, T., Blain, H., Buchon, D., Chapurlat, R. D., Debiais, F., Féron, J.-M., Gauvain, J. B., Guggenbuhl, P., et al. (2018) · Revue du Rhumatisme · doi:10.1016/j.rhum.2018.02.005 · Cited by 44
Self-citationUpdate on the treatment of post-menopausal osteoporosis
Cole, Z. A., Dennison, E. M., & Cooper, C. C. (2008) · British Medical Bulletin · doi:10.1093/bmb/ldn017 · Cited by 44
Vertebral compression fractures: manage aggressively to prevent sequelae.
Mazanec, D. J., Podichetty, V. K., Mompoint, A., & Potnis, A. (2003) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.70.2.147 · Cited by 44
Selective estrogen receptor modulators (SERMS)
Díez‐Pérez, A. (2006) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302006000400017 · Cited by 44
Lanza, F. L., Rack, M. F., Li, Z., Krajewski, S. A., & BLANK, M. A. (2000) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2000.00887.x · Cited by 44
Comparing Therapies for Postmenopausal Osteoporosis Prevention and Treatment
Eichner, S. F., Lloyd, K. B., & Timpe, E. M. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1c246 · Cited by 44
Lewiecki, E. M., Babbitt, A. M., Piziak, V. K., Ozturk, Z. E., & Bone, H. G. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.04.009 · Cited by 44
Osteoporosis diagnosis and screening
Singer, A. J. (2006) · Clinical cornerstone · doi:10.1016/s1098-3597(06)80061-x · Cited by 43
Raloxifene use in clinical practice: efficacy and safety
Goldstein, S. R., Duvernoy, C. S., Calaf, J., Adachi, J. D., Mershon, J. L., Dowsett, S. A., Agnusdei, D., & Stuenkel, C. A. (2009) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3181883dae · Cited by 43
Vertebral deformation in urban Swedish men and women: Prevalence based on 797 subjects
Hasserius, R., Redlund-Johnell, I., Mellström, D., Johansson, C., Nilsson, B. E., & Johnell, O. (2001) · Acta Orthopaedica Scandinavica · doi:10.1080/00016470152846619 · Cited by 43
Systematic assessment of the human osteoblast transcriptome in resting and induced primary cells
Grundberg, E., Brändström, H., Lam, K. C. L., Gurd, S., Ge, B., Harmsen, E., Kindmark, A., Ljunggren, Ö., Mallmin, H., Nilsson, O., et al. (2008) · Physiological Genomics · doi:10.1152/physiolgenomics.00028.2008 · Cited by 43
Ettinger, B. B., Hillier, T. A., Pressman, A. R., Che, M., & Hanley, D. A. (2005) · Journal of Women s Health · doi:10.1089/jwh.2005.14.159 · Cited by 43
Practical guidance for the use of bisphosphonates in osteoporosis
Compston, J. E. (2020) · Bone · doi:10.1016/j.bone.2020.115330 · Cited by 42
McCloskey, E. V., Paterson, A. H. G., Kanis, J. А., Tähtelä, R., & Powles, T. J. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.12.003 · Cited by 42
New Approaches to the Treatment of Osteoporosis
Silva, B. C. C., & Bilezikian, J. P. (2010) · Annual Review of Medicine · doi:10.1146/annurev-med-061709-145401 · Cited by 42
Osteoporosis in Postmenopausal Women: Considerations in Prevention and Treatment
Sanders, S., & Geraci, S. A. (2013) · Southern Medical Journal · doi:10.1097/smj.0b013e3182a0df8b · Cited by 42
Dual X-ray Absorptiometry: Cross-Calibration of a New Fan-Beam System
Blake, G. M., Harrison, E. J., & Adams, J. E. (2004) · Calcified Tissue International · doi:10.1007/s00223-004-0169-y · Cited by 42
Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate
Watts, N. B., Lindsay, R., Li, Z., Kasibhatla, C., & Brown, J. P. (2003) · Osteoporosis International · doi:10.1007/s00198-003-1401-8 · Cited by 42
Gani, L. U., Sritara, C., Blank, R. D., Chen, W., Gilmour, J., Dhaliwal, R., & Gill, R. S. (2023) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2023.101440 · Cited by 41
Curtis, J. R., Westfall, A. O., Cheng, H. T., Saag, K. G., & Delzell, E. (2008) · Osteoporosis International · doi:10.1007/s00198-008-0772-2 · Cited by 41
Lenaerts, L., & van Lenthe, H. (2009) · Philosophical Transactions of the Royal Society A Mathematical Physical and Engineering Sciences · doi:10.1098/rsta.2008.0302 · Cited by 41
Chen, L.-H., Hsieh, M.-K., & Chen, W. (2013) · Biomedical Journal · doi:10.4103/2319-4170.112544 · Cited by 41
Jia, H., Li, W., & Zhao, K. (2006) · Analytica Chimica Acta · doi:10.1016/j.aca.2006.01.077 · Cited by 41
Kinov, P. S., Tivchev, P., Doukova, P., & Leithner, A. (2006) · PubMed · Cited by 41
Effect of Teriparatide on Bone Formation in the Human Femoral Neck
Cosman, F., Dempster, D. W., Nieves, J. W., Zhou, H., Zion, M., Roimisher, C., Houle, Y., Lindsay, R., & Bostrom, M. P. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3698 · Cited by 41
Recent Developments in Bisphosphonate Therapy
Silverman, S. L., & Maricic, M. J. (2007) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2006.12.003 · Cited by 41
Emkey, R. D., Delmas, P. D., Bolognese, M. A., Borges, J. L. C., Cosman, F., Ragi-Eis, S., Recknor, C. P., Zerbini, C. A. F., Neate, C., Sedarati, F., et al. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.04.018 · Cited by 41
DiVittorio, G., Jackson, K. L., Chindalore, V. L., Welker, W., & Walker, J. B. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.2006.26.1.104 · Cited by 41
Is Radiographic Vertebral Fracture a Risk Factor for Mortality?
Trone, D. W., Kritz‐Silverstein, D. C., von Mühlen, D. G., Wingard, D., & Barrett-Connor, E. L. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm206 · Cited by 41
Matsumoto, T., Shiraki, M., Hagino, H., Iinuma, H., & Nakamura, T. (2006) · Osteoporosis International · doi:10.1007/s00198-006-0159-1 · Cited by 41
Shiraki, M., & Itabashi, A. (2009) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-008-0034-6 · Cited by 40
Recommendations by the Spanish Society of Rheumatology on Osteoporosis
Naranjo, A., Fontecha, P. D. D. C., Acín, M. P. A., Rodríguez, L. M. A., Casado, E., Castañeda, S., Aresté, J. F., Gifre, L., Vaquero, C. G., Rodríguez, G. C., et al. (2019) · Reumatología Clínica (English Edition) · doi:10.1016/j.reumae.2018.09.011 · Cited by 40
Tanriverdi, H. A., Barut, A., & Sarıkaya, S. (2004) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2004.08.007 · Cited by 40
Adachi, J. D., Hanley, D. A., Lorraine, J., & YU, M. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.09.024 · Cited by 40
TAWARA, D., Sakamoto, J., Murakami, H., Kawahara, N., Juhachi, O. D. A., & Tomita, K. (2009) · Journal of the mechanical behavior of biomedical materials/Journal of mechanical behavior of biomedical materials · doi:10.1016/j.jmbbm.2009.03.001 · Cited by 40
Statins and Osteoporosis: A Clinical Review
Gonyeau, M. J. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.25.2.228.56954 · Cited by 40
Osteoporosis and breast cancer
Fontanges, É., Fontana, A., & Delmas, P. D. (2003) · Joint Bone Spine · doi:10.1016/j.jbspin.2003.02.001 · Cited by 40
Pharmacologic and nonpharmacologic management of osteoporosis
Levine, J. P. (2006) · Clinical cornerstone · doi:10.1016/s1098-3597(06)80064-5 · Cited by 40
The gastrointestinal tolerability and safety of oral bisphosphonates
Marshall, J. K. (2002) · Expert Opinion on Drug Safety · doi:10.1517/14740338.1.1.71 · Cited by 40
Clinical Use of Teriparatide in the Real World: Initial Insights
Miller, P. D., Bilezikian, J. P., Deal, C. L., Harris, S. T., & Pacifici, R. (2004) · Endocrine Practice · doi:10.4158/ep.10.2.139 · Cited by 40
Developments in the pharmacotherapeutic management of osteoporosis
Close, P., Neuprez, A., & Reginster, J. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.12.1603 · Cited by 40
Self-citationThe effects of strength training and raloxifene on bone health in aging ovariectomized rats
Stringhetta-Garcia, C. T., Singulani, M. P., dos Santos, L. F., Louzada, M. J. Q., Nakamune, A. C. S., Chaves-Neto, A. H., Rossi, A. C., Ervolino, E., & Dornelles, R. C. M. (2016) · Bone · doi:10.1016/j.bone.2015.11.023 · Cited by 39
Qiang, G., Zhang, C., Wang, J., Wei, Q., Wei, Q., Miyamoto, A., Zhu, S., & He, C. (2020) · Archives of Osteoporosis · doi:10.1007/s11657-020-0705-z · Cited by 39
Narongroeknawin, P., Patkar, N. M., Shakoory, B., Jain, A., Curtis, J. R., Delzell, E., Lander, P., Lopez‐Ben, R., Pitt, M. J., Safford, M. M., et al. (2011) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2011.09.001 · Cited by 39
Osteoporosis in Systemic Lupus Erythematosus Mechanisms
Lee, C., & Ramsey‐Goldman, R. (2005) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2005.01.004 · Cited by 39
Calcium Citrate and Vitamin D in the Treatment of Osteoporosis
Gómez, J. M., Blanch‐Rubió, J., Díaz Curiel, M., & Díez‐Pérez, A. (2011) · Clinical Drug Investigation · doi:10.1007/bf03256927 · Cited by 39
Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis
Lewiecki, E. M. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.540565 · Cited by 39
A 55-Year-Old Woman With Osteopenia
Cummings, S. R. (2006) · JAMA · doi:10.1001/jama.296.21.2601 · Cited by 39
Steinbuch, M., D’Agostino, R. B., Mandel, J. S., Gabrielson, E., McClung, M. R., Stemhagen, A., & Hofman, A. (2002) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2002.1550 · Cited by 39
Fleisch, H. A., Reszka, A. A., Rodan, G. A., & Rogers, M. J. (2002) · Elsevier eBooks · doi:10.1016/b978-012098652-1/50180-3 · Cited by 39
Guidelines for the management of postmenopausal osteoporosis for GPs.
O’Neill, S., MacLennan, A. H., Bass, S. L., Diamond, T., Ebeling, P. R., Findlay, D. M., Flicker, L. A., Markwell, A., Nowson, C. A., Pocock, N. A., et al. (2004) · PubMed · Cited by 39
Gilfillan, C. P., Strauss, B. J., Rodda, C. P., Bowden, D. K., Kean, A.-M., Obaid, M. I., & Crawford, B. A. L. (2006) · Calcified Tissue International · doi:10.1007/s00223-006-0314-x · Cited by 38
Ramalho‐Ferreira, G., Faverani, L. P., Grossi‐Oliveira, G. A., Okamoto, T., & Okamoto, R. (2015) · Journal of Biomedical Optics · doi:10.1117/1.jbo.20.3.038003 · Cited by 38
Osteoporose pós-menopausa: opções terapêuticas
Russo, L. A. T. (2001) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302001000400013 · Cited by 38
Vesselplasty: A New Technical Approach to Treat Symptomatic Vertebral Compression Fractures
Flors, L., Lonjedo, E., Leiva‐Salinas, C., Martí‐Bonmatí, L., Martínez-Rodrigo, J. J., López-Pérez, E., Figueres, G., & Rzadkowolsky-Raoli, I. (2009) · American Journal of Roentgenology · doi:10.2214/ajr.08.1503 · Cited by 38
Assessment of non-vertebral fracture risk in postmenopausal women
Roux, C., Briot, K., Horlait, S., Varbanov, A. R., Watts, N. B., & Boonen, S. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.064071 · Cited by 38
Self-citationVilla, J. C., Gianakos, A. L., & Lane, J. M. (2015) · HSS Journal® The Musculoskeletal Journal of Hospital for Special Surgery · doi:10.1007/s11420-015-9469-1 · Cited by 38
Secondary Prevention of Fragility Fractures: Are We Following the Guidelines?
Prasad, N., Sunderamoorthy, D., Martin, J. C., & Murray, J. M. (2006) · Annals of The Royal College of Surgeons of England · doi:10.1308/003588406x116891 · Cited by 38
Postmenopausal osteoporosis. What have we learned since the introduction of bisphosphonates?
Chaiamnuay, S., & Saag, K. G. (2006) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-006-9008-y · Cited by 38
Adachi, J. D., Rizzoli, R., Boonen, S., Li, Z., Meredith, M. P., & Chesnut, C. H. (2005) · Aging Clinical and Experimental Research · doi:10.1007/bf03324588 · Cited by 38
Ishizaka, K., Machida, T., Kobayashi, S., Kanbe, N., Kitahara, S., & Yoshida, K. (2007) · International Journal of Urology · doi:10.1111/j.1442-2042.2007.01911.x · Cited by 38
Pharmacologic prevention of osteoporotic fractures.
Zizic, T. M. (2004) · PubMed · Cited by 38
Vilaça, T., Schini, M., Lui, L., Ewing, S. K., Thompson, A. R., Vittinghoff, E., Bauer, D. C., Eastell, R., Black, D. M., & Bouxsein, M. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae126 · Cited by 37
Self-citationOrozco, C., & Maalouf, N. M. (2012) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2012.09.001 · Cited by 37
Javaid, M. K. (2021) · Aging Clinical and Experimental Research · doi:10.1007/s40520-021-01844-9 · Cited by 37
Müeller, D., & Gandjour, A. (2009) · Value in Health · doi:10.1111/j.1524-4733.2009.00577.x · Cited by 37
Ström, O., Borgström, F., Kleman, M., McCloskey, E. V., Odén, A., Johansson, H., & Kanis, J. A. (2010) · Bone · doi:10.1016/j.bone.2010.05.020 · Cited by 37
Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors
Roux, C., Goldstein, J. L., Zhou, X., Klemes, A. B., & Lindsay, R. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1574-5 · Cited by 37
Self-citationWu, Y., Adeeb, S., Duke, M. J. M., Munoz-Paniagua, D., & Doschak, M. R. (2013) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3c59h · Cited by 37
Keshishian, A. V., Boytsov, N. N., Burge, R. T., Krohn, K., Lombard, L., Zhang, X., Xie, L., & Baser, O. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4072-6 · Cited by 37
Shiraki, M., Fukunaga, M., KUSHIDA, K., Kishimoto, H., Taketani, Y., MINAGUCHI, H., Inoue, T. M. N., Morita, R., Morii, H., Yamamoto, K., et al. (2003) · Osteoporosis International · doi:10.1007/s00198-002-1369-9 · Cited by 37
Bauss, F., & Schimmer, R. C. (2006) · PubMed Central · Cited by 37
Evaluation of Vertebral Fractures on Lateral Chest Radiographs of Inner-City Postmenopausal Women
Mui, L., Haramati, L. B., Alterman, D. D., Haramati, N., Zelefsky, M. N., & Hamerman, D. (2003) · Calcified Tissue International · doi:10.1007/s00223-003-0064-y · Cited by 37
Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis
Krege, J. H., & Wan, X. (2011) · Bone · doi:10.1016/j.bone.2011.10.018 · Cited by 36
Oral Bisphosphonate Use Increases the Risk for Inflammatory Jaw Disease: A Cohort Study
Vestergaard, P., Schwartz, K., Rejnmark, L., Mosekilde, L., & Pinholt, E. M. (2011) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2011.02.093 · Cited by 36
Giusti, A. (2014) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-014-0584-8 · Cited by 36
Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women
Osaki, M., Tatsuki, K., Hashikawa, T., Norimatsu, T., Chiba, K., Motokawa, S., Furuichi, I., Doiguchi, Y., Aoyagi, K., & Shindo, H. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1556-7 · Cited by 36
Boonen, S., Lorenc, R. S., Wenderoth, D., Stoner, K. J., Eusebio, R. A., & ORWOLL, E. S. (2012) · Bone · doi:10.1016/j.bone.2012.06.016 · Cited by 36
Update on bazedoxifene: a novel selective estrogen receptor modulator.
Biskobing, D. M. (2007) · PubMed Central · Cited by 36
Cosman, F. (2009) · Endocrine Practice · doi:10.4158/ep08306.orr1 · Cited by 36
New developments in the treatment of osteoporosis
Eriksen, E. F., Halse, J., & Moen, M. H. (2012) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/j.1600-0412.2012.01473.x · Cited by 35
Current options for the management of postmenopausal osteoporosis
Lecart, M.-P., & Reginster, J. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.618123 · Cited by 35
Self-citationBisphosphonates and mortality: confounding in observational studies?
Bergman, J., Nordström, A., Hommel, A., Kivipelto, M., & Nordström, P. (2019) · Osteoporosis International · doi:10.1007/s00198-019-05097-1 · Cited by 35
Aurich‐Barrera, B., Wilton, L., Harris, S., & Shakir, S. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1986-1 · Cited by 35
Osteoporosis treatment and fracture incidence: the ICARO longitudinal study
Adámi, S., Isaia, G., Luisetto, G., Minisola, S., SINIGAGLIA, L., Silvestri, S., Agnusdei, D., Gentilella, R., Nuti, R., & on behalf of the ICARO Study Group (2008) · Osteoporosis International · doi:10.1007/s00198-008-0566-6 · Cited by 35
VALIMAIKI, M., FARRERONSMINGUELLA, J., Halse, J., Kröger, H., Maroni, M. M. S., Mulder, H., Muñoz‐Torres, M., Sääf, M., & SNORREOFJORD, E. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.09.017 · Cited by 35
Perkins, A. C., WILSON, C. G., Frier, M., Blackshaw, P. E., Dansereau, R. J., Vincent, R. M., Wenderoth, D., Hathaway, S., Li, Z., & Spiller, R. E. (2001) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(01)00722-0 · Cited by 35
Majima, T., Komatsu, Y., Doi, K., Takagi, C., Shigemoto, M., Fukao, A., Morimoto, T., Corners, J., & Nakao, K. (2006) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-005-0655-y · Cited by 35
Delmas, P. D. (2002) · Bone · doi:10.1016/s8756-3282(01)00667-6 · Cited by 35
Delmas, P. D., Calvo, G., Boers, M., Abadie, E., Avouac, B. P., Kahan, A., Kaufman, J., Laslop, A., Lekkerkerker, J. F. F., Nilsson, P. G., et al. (2002) · Osteoporosis International · doi:10.1007/s198-002-8331-3 · Cited by 35
Self-citation
Metadata
- Authors
- Reginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., & Eastell, R.
- Affiliations
- University of Liège (BE)
- The University of Sydney (AU)
- Hôpital Cochin (FR)
- University of Florence (IT)
- Procter & Gamble (United States) (US)
- University of Sheffield (GB)
- Venue
- Osteoporosis International
- Published
- 2000-01-01
- Volume
- 11
- Issue
- 1
- Pages
- 83-91
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- OpenAlex
- W1526826623
- Cited by
- 1,580
- References
- 29
- Citations by year
- 2026: 14 · 2025: 17 · 2024: 19 · 2023: 25 · 2022: 26 · 2021: 31 · 2020: 38 · 2019: 30 · 2018: 36 · 2017: 27 · 2016: 44 · 2015: 50 · 2014: 47 · 2013: 69 · 2012: 66
- FWCI
- 78.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Osteoporosis International (publishedVersion)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- risedronate, postmenopausal osteoporosis, vertebral fractures, fracture prevention, bisphosphonates, bone mineral density, non-vertebral fractures, calcium and vitamin D supplementation, gastrointestinal adverse effects, drug safety
- MeSH terms
- Risedronic Acid, Aged, Aged, 80 and over, Algorithms, Australia, Calcium Channel Blockers, Double-Blind Method, Europe, Female, Humans, Middle Aged, Etidronic Acid, Absorptiometry, Photon, Bone Density, Osteoporosis, Postmenopausal, Spinal Fractures, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.